Heidelberg Pharma AG - Company Profile

Powered by

All the data and insights you need on Heidelberg Pharma AG in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Heidelberg Pharma AG Strategy Report

  • Understand Heidelberg Pharma AG position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Heidelberg Pharma AG: Overview

Select Item

Heidelberg Pharma AG (Heidelberg Pharma) is a biopharmaceutical company that develops novel therapeutics for the treatment and specific detection of various cancers. Heidelberg Pharma’s pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, non-hodgkin lymphoma, blood cancers, generic diseases and solid tumors. Through its subsidiary, Heidelberg Pharma Research GmbH provides preclinical contract research services and to develop the toxin Amanitin into oncology therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. Heidelberg Pharma is headquartered in Ladenburg, Germany.

 Gain a 360-degree view of Heidelberg Pharma AG and make more informed decisions for your business Gain a 360-degree view of Heidelberg Pharma AG and make more informed decisions for your business Find out more
Headquarters Germany
Address Schriesheimer Strasse 101, Ladenburg, Baden-Wurttemberg, 68526
Website www.heidelberg-pharma.com
Telephone 49 6203 10090
No of Employees 101
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange HPHA (ETR)
Revenue (2022) $21.9M 958% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 24.6% (2022 vs 2021)
Market Cap* $186.1M
Net Profit Margin (2022) XYZ 92.9% (2022 vs 2021)
* As of and is in US$
View Heidelberg Pharma AG financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Heidelberg Pharma AG premium industry data and analytics

30+

Pipeline Drugs

Identify which of Heidelberg Pharma AG’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Clinical Trials

Determine Heidelberg Pharma AG go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

10+

Catalyst Calendar

Proactively evaluate Heidelberg Pharma AG’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Heidelberg Pharma AG’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
Pipeline
ATAC Platform:
HDP-101 - Multiple Myeloma (DLBCL/CLL)
XYZ
XYZ
XYZ
Understand Heidelberg Pharma AG portfolio and identify potential areas for collaboration Understand Heidelberg Pharma AG portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In December, the company entered into a research and option agreement with Binghamton University on a novel and proprietary immunostimulatory technology platform.
2021 Official Trials/Tests In July, Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101.
2021 Official Trials/Tests In February, company to start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Heidelberg Pharma AG Merck KGaA Biotest AG Baxter Oncology GmbH MediGene AG
Headquarters Germany Germany Germany Germany Germany
City Ladenburg Darmstadt Dreieich Halle Planegg
State/Province Baden-Wurttemberg Hessen Hessen Nordrhein-Westfalen Bayern
No. of Employees 101 63,297 2,307 - 87
Entity Type Public Public Public Private Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Christof Hettich, Ph.D. Chairman Executive Board 2020 -
Dr. Jan Schmidt-Brand Chief Executive Officer Senior Management 2014 -
Walter Miller Chief Financial Officer Senior Management 2023 -
Andras Strassz Chief Medical Officer Senior Management 2021 -
Dr. Andreas Pahl Chief Scientific Officer Senior Management 2016 -
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Heidelberg Pharma AG key executives to enhance your sales strategy Gain insight into Heidelberg Pharma AG key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward